The share reached a 52-week high of Rs 1,804.70 on August 17, 2023, and a 52-week low of Rs 1,115.15 on October 28, 2022, respectively.-Ajanta Pharma
Ajanta Pharma shares experienced a 1 percent increase to Rs 1,748.90 in the early trade on August 31 following the USFDA approval of its Topiramate extended release capsules.
The corporation has obtained very last approval from the us food and Drug administration (USFDA) to market the tablets in 25 mg, 50 mg, a hundred mg, and 200 mg versions.
The regular form of Trokendi XR from Supernus Prescribed Drugs Inc.
As according to the settlement with the innovator, Ajanta can launch Topiramate on February 1, 2026 or in advance under sure occasions, the organisation said.
As according to the settlement with the innovator, Ajanta can launch Topiramate on February 1, 2026 or in advance under sure occasions, the organisation said.
Ajanta Pharma expands on the USFDA’s approval of topiramate capsules. 22 ANDAs are pending USFDA clearance, and it also has 2 tentative approvals.
